Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Weimbs

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of Cellular and Molecular Medicine|October 28, 2020
The carboxy-terminus of the human ARPKD protein fibrocystin can control STAT3 signalling by regulating SRC-activationClaudia Dafinger, Amrei M Mandel, Alina Braun, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2022
Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progressionMasaw Akbari, Jonathan D West, Nicholas Doerr, et al.
Plos One|August 26, 2016
Regulation of Polycystin-1 Function by Calmodulin BindingNicholas Doerr, Yidi Wang, Kevin R Kipp, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Correction to: Kidney Week 2025 Abstract Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD SA-PO0579Haruna Kawano, Wakana Koizumi, Yan Lu, et al.
The Journal of Clinical Investigation|May 1, 2025
Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney diseaseJacob A Torres, Mina Rezaei, Caroline Broderick, et al.
The Journal of Clinical Investigation|July 31, 2019
Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney diseaseJacob A Torres, Mina Rezaei, Caroline Broderick, et al.
Clinical Kidney Journal|June 6, 2022
Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effectsSebastian Strubl, Simon Oehm, Jacob A Torres, et al.
Iscience|September 24, 2024
β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney diseaseJacob A Torres, Nickolas Holznecht, David A Asplund, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2006
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney diseaseJonathan M Shillingford, Noel S Murcia, Claire H Larson, et al.
Cell Reports. Medicine|November 7, 2023
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trialSadrija Cukoski, Christoph Heinrich Lindemann, Sita Arjune, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of Cellular and Molecular Medicine|October 28, 2020
The carboxy-terminus of the human ARPKD protein fibrocystin can control STAT3 signalling by regulating SRC-activationClaudia Dafinger, Amrei M Mandel, Alina Braun, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2022
Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progressionMasaw Akbari, Jonathan D West, Nicholas Doerr, et al.
Plos One|August 26, 2016
Regulation of Polycystin-1 Function by Calmodulin BindingNicholas Doerr, Yidi Wang, Kevin R Kipp, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Correction to: Kidney Week 2025 Abstract Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD SA-PO0579Haruna Kawano, Wakana Koizumi, Yan Lu, et al.
The Journal of Clinical Investigation|May 1, 2025
Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney diseaseJacob A Torres, Mina Rezaei, Caroline Broderick, et al.
The Journal of Clinical Investigation|July 31, 2019
Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney diseaseJacob A Torres, Mina Rezaei, Caroline Broderick, et al.
Clinical Kidney Journal|June 6, 2022
Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effectsSebastian Strubl, Simon Oehm, Jacob A Torres, et al.
Iscience|September 24, 2024
β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney diseaseJacob A Torres, Nickolas Holznecht, David A Asplund, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2006
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney diseaseJonathan M Shillingford, Noel S Murcia, Claire H Larson, et al.
Cell Reports. Medicine|November 7, 2023
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trialSadrija Cukoski, Christoph Heinrich Lindemann, Sita Arjune, et al.
Pageof 8